ScreenerHero

OSE OSE Immunotherapeutics SA

EPA · FR · Healthcare · Biotechnology · ose-immuno.com
2.114EUR-2.76%Mkt Cap: 56.83M $P/E: —

OSE Immunotherapeutics SA, a clinical-stage biotechnology company, develops immunotherapies in the areas of immune-oncology and immune-inflammation in France and internationally. The company's products include Tedopi tha…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated - Common Stock
$127.85BUSDP/E 29.4
MRNA
Moderna, Inc. - Common Stock
$75.86BUSD
REGN
Regeneron Pharmaceuticals, Inc. - Common Stock
$75.69BUSDP/E 18.2
ARGX
argenx SE - American Depositary Shares
$57.51BUSDP/E 35.1
ARGX
ARGENX SE
$55.45BUSDP/E 35.2
RVMD
Revolution Medicines, Inc. - Common Stock
$44.29BUSD
UCB
UCB SA
$42.34BUSDP/E 18.1
ONC
BeOne Medicines Ltd. - American Depositary Shares
$40.51BUSDP/E 63.9
RPRX
Royalty Pharma plc - Class A Ordinary Shares
$33.03BUSDP/E 30.7
ALNY
Alnylam Pharmaceuticals, Inc. - Common Stock
$29.40BUSDP/E 38.3
ROIV
Roivant Sciences Ltd. - Common Shares
$25.80BUSD
BNTX
BioNTech SE - American Depositary Shares
$24.34BUSD
INSM
Insmed Incorporated - Common Stock
$24.27BUSD
INCY
Incyte Corporation - Common Stock
$23.37BUSDP/E 14.7
GMAB
Genmab A/S - American Depositary Shares
$21.69BUSDP/E 27.4
GMAB
Genmab A/S
$20.52BUSDP/E 27.1
JAZZ
Jazz Pharmaceuticals plc - Ordinary Shares
$15.30BUSDP/E 16.1
ASND
Ascendis Pharma A/S - Ordinary Share
$14.99BUSDP/E 17.8
EXEL
Exelixis, Inc. - Common Stock
$14.47BUSDP/E 18.4
SMMT
Summit Therapeutics Inc. - Common Stock
$13.37BUSD

Key Statistics

Company
Market Cap56.83M USD
Enterprise Value41.46M USD
Revenue (TTM)2.92M USD
Gross Profit2.59M USD
Net Income (TTM)-40.97M USD
Revenue/Share0.12 EUR
Last Price2.114 EUR
Fiscal Year EndDec 2025
MR QuarterDec 2024
Employees64
CountryFR
SectorHealthcare
IndustryBiotechnology
ISINFR0012127173
Valuation
P/E (Trailing)—
P/E (Forward)-1.91
PEG—
EV/EBITDA-1.02
EV/Revenue14.18
P/S19.98
P/B1.76
EPS (TTM)-1.69
EPS (Forward)-1.14
52W Range
2.0980% of range7.180
52W High7.180 EUR
52W Low2.098 EUR
Profitability
Gross Margin88.70%
Oper. Margin-2272.16%
EBITDA Margin0.00%
Profit Margin-1439.06%
ROE-135.78%
ROA-47.79%
Growth
Revenue Growth-0.80%
Earnings Growth—
Cash Flow & Leverage
Operating CF-37.00M USD
CapEx (TTM)106.52K USD
FCF Margin-662.85%
FCF Yield-34.12%
Net Debt-14.11M USD
Net Debt/EBITDA0.35
Balance Sheet
Debt/Equity1.27
Current Ratio1.28
Quick Ratio1.17
Book Value/Sh1.24 EUR
Cash/Share2.51 EUR
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 EUR
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.0 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)12.70 EUR
Upside (mean)+500.8%
Target Range8.200 EUR – 21.00 EUR
8.200+500.8% to mean21.00
# Analysts4
Ownership
Shares Out.24.73M
Float17.31M
Insiders25.37%
Institutions2.69%
Technical
SMA 503.011 (-29.8%)
SMA 2003.775 (-44.0%)
Beta0.83
S&P 52W Chg13.94%
Avg Vol (30d)132.95K
Avg Vol (10d)175.88K
Technical Indicators
RSI (14)20.0
MACD-0.2391
MACD Signal-0.2070
MACD Hist.-0.0321
BB Upper3.097 EUR
BB Middle2.564 EUR
BB Lower2.031 EUR
BB Width41.56%
ATR (14)0.1384 EUR
Vol Ratio (20d)0.83x